Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma

NCT06657157 · clinicaltrials.gov ↗
RECRUITING
Status
80
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Comprehensive Cancer Center Munich (CCCM)

Collaborators